Nextera is very pleased to announce that the Norwegian Research Council (NRC) has awarded a grant through the Innovation Project for the Industrial Sector (IPN) to support our continued development of TCR-Like antibodies as novel therapy in autoimmune diseases such as Celiac Disease and Rheumatoid arthritis.
“This grant project is a natural expansion of our already strong T cell immunology focus in drug discovery, further validates Nextera’s commercial pathway, and will facilitate our differentiated development of TCR-Like antibody tolerizing therapy in autoimmunity.” Geir Åge Løset, PhD, co-founder and CEO/CSO Nextera AS.
